RXi Pharmaceuticals Corp Share Price Nasdaq
Equities
US74979C8082
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 3.18M 253M |
---|---|---|---|---|---|
Net income 2024 * | -13M -1.04B | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.19
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.41% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 18/06/12 |
Caitlin Kontulis
DFI | Director of Finance/CFO | - | - |
James Cardia
CTO | Chief Tech/Sci/R&D Officer | - | 14/09/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Bitterman
CEO | Chief Executive Officer | 73 | 18/06/12 |
Director/Board Member | 73 | 01/05/22 | |
Curtis Lockshin
BRD | Director/Board Member | 64 | 17/04/13 |
1st Jan change | Capi. | |
---|---|---|
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+44.36% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |